Vertex Falls, Hims Sinks, Molson Coors Cuts Outlook
On this edition of Stock Movers:- Vertex Pharmaceuticals Inc. (VRTX) shares fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a chronic pain condition. Vertex has been trying to diversify beyond its core business of cystic fibrosis treatments. A key part of has been its new non-opioid pain drug, Journavx, which got US regulatory clearance in January. It was the first new type of painkiller to reach the US market in more than two decades. Shares of Vertex fell as much as…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.